| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
argenx (NASDAQ:ARGX) reported quarterly earnings of $5.18 per share which beat the analyst consensus estimate of $4.30 by 20.44...
argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from...
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART's potential to treat broad set of myasthenia gravis ...
Wedbush analyst David Nierengarten maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target from $800 to...
Morgan Stanley analyst Matthew Harrison maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $7...